RBI 8000
Alternative Names: RBI-8000Latest Information Update: 17 Sep 2021
At a glance
- Originator Replicate Bioscience
- Class Anti-inflammatories; RNA
- Mechanism of Action Inflammasome modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 16 Sep 2021 RBI 8000 is available for licensing as of 16 Sep 2021. https://replicatebioscience.com/partnerships.html
- 08 Sep 2021 Replicate Bioscience plans a clinical trial for Autoimmune disorders and Inflammation (IM)
- 08 Sep 2021 Early research in Autoimmune disorders in USA (IM) (Replicate Bioscience pipeline, September 2021)